Biotechnology company smartbax has announced it has raised €4.7 million to advance a novel antibiotic compound through preclinical stage.  The pre-Series A financing round was led by new investors Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators as well as existing investors.  The financing will support the progression of smartbax’s pipeline […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!